Comparing across cohorts, there was a suggestion of improved ORR in less heavily pre-treated patients (ORR 21.4% vs. 5.3%) in Cohort B vs. all-comers in Cohort A. This was consistent with other similar phase 1 trials evaluating avelumab (JAVELIN study)[17] and atezolizumab (PCD4989g trial)[18] as monotherapy in metastatic TNBC, suggesting clinical benefit when used in earlier lines of treatment and PD-L1 expressing tumours. Here, CD274 is linked to neoplasm.